NDA 205874/S-13

NOTIFICATION OF
NON-COMPLIANCE WITH PREA

Keryx Biopharmaceuticals, Inc.
Attention: Gunjita Joshi, M.S.
Specialist, Regulatory Affairs
245 First Street Suite 1400
Cambridge, MA 02142

Dear Gunjita Joshi:

Please refer to your supplemental new drug application (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (the Act) for Auryxia (ferric citrate) tablets, which was approved on November 6, 2017.

The Agency has determined that you have failed to meet the postmarketing requirement (PMR) of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment for PMR 3286-1, which was deferred until August 31, 2024.

Under the provisions of section 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 355c(d)(1)], you must respond in writing within 45 calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable, which should be identified as a "**DEFERRAL EXTENSION REQUESTED**" in your response. We note that you requested a deferral extension on February 9, 2024; however, we have determined that your request did not qualify for an extension.

In accordance with the FD&C Act, FDA will post this letter and your response to the website at https://www.fda.gov/drugs/development-resources/non-compliance-letters-under-505bd1-federal-food-drug-and-cosmetic-act with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter. Please identify your response to this letter as a "**RESPONSE TO PREA NON-COMPLIANCE LETTER.**" To facilitate our review, submit this information to your NDA with a cross-reference letter to the investigational new drug application (IND) to which your protocol has been submitted.

If you have any questions, please contact Youngeun (Catherine) Kim, Regulatory Health Project Manager, at 301-796-8164 or email youngeun.kim@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Tanya Wroblewski, MD
Deputy Director
Division of Nonmalignant Hematology
Office of Cardiology, Hematology,
Endocrinology, and Nephrology
Office of New Drugs
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TANYA M WROBLEWSKI
09/20/2024 02:41:14 PM